Valuation : CombiGene AB

Market Cap 4.38Cr 45.74L 39.36L 37.03L 33.83L 63.28L 43Cr 63.46L 1.7Cr 22Cr 1.72Cr 1.68Cr 71Cr P/E 2024
-1.05x
P/E 2025 -3.62x
Enterprise Value 3.79Cr 39.64L 34.11L 32.09L 29.31L 54.84L 37Cr 54.99L 1.47Cr 19Cr 1.49Cr 1.46Cr 62Cr EV / Sales 2024
-13.3x
EV / Sales 2025 128x
Free-Float
53.9%
Yield 2024
8.4%
Yield 2025 88.5%
1 day-0.90%
1 week-1.78%
Current month-5.15%
1 month+0.91%
3 months-2.64%
6 months+6.25%
Current year-2.21%
1 week 2.2
Extreme 2.2
2.34
1 month 2.03
Extreme 2.03
2.34
Current year 1.75
Extreme 1.75
2.6
1 year 1.75
Extreme 1.75
2.87
3 years 1.27
Extreme 1.27
6.49
5 years 1.27
Extreme 1.27
20.05
10 years 1.27
Extreme 1.27
147
Manager TitleAgeSince
Chief Executive Officer 48 31/07/2025
Director TitleAgeSince
Director/Board Member 54 10/12/2024
Chairman 55 11/06/2026
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
-0.90%-1.78%-11.24%-63.53% 45.74L
-1.79%-2.27%+50.90%+89.03% 6.8TCr
-2.06%-0.18%+41.53%+88.17% 6.49TCr
-0.31%+6.54%-11.39%+457.82% 2.76TCr
-3.00%-2.90%+39.40%+9.41% 2.57TCr
+0.86%+1.65%+0.25%-14.78% 2.61TCr
-1.46%+0.42%+24.07%-18.70% 2.01TCr
-2.96%-15.21%+210.71%+370.84% 1.72TCr
-1.49%-4.88%-0.41%+530.26% 1.49TCr
-0.20%+8.37%+57.87%+159.50% 1.46TCr
Average -1.33%+0.05%+40.17%+160.80% 2.79TCr
Weighted average by Cap. -1.52%+0.18%+42.29%+145.08%

Financials

2024 2025
Net sales 19.99L 2L 2L 2L 2L 3L 1.97Cr 3L 8L 1.01Cr 8L 8L 3.26Cr 3L 31.78T 27.34T 25.73T 23.5T 43.96T 30L 44.08T 1L 15.39L 1L 1L 49.59L
Net income -4.49Cr -46.91L -40.37L -37.98L -34.69L -64.9L -44Cr -65.08L -1.74Cr -23Cr -1.76Cr -1.72Cr -73Cr -1.24Cr -12.92L -11.12L -10.46L -10L -17.87L -12Cr -17.92L -47.96L -6.26Cr -48.51L -47.45L -20Cr
Net Debt -7.37Cr -77.09L -66.33L -62.41L -57.01L -1.07Cr -73Cr -1.07Cr -2.86Cr -37Cr -2.89Cr -2.83Cr -120.3Cr -58.42L -6L -5L -5L -5L -8L -5.77Cr -8L -22.67L -2.96Cr -22.93L -22.43L -9.53Cr
Logo CombiGene AB
Larkberget AB, formerly Combigene AB, is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company specializes in development of treatments for neurological disorders. The Company's platform comprises the use of gene therapy vectors delivering a combination of transgenes encoding two or more of neuropeptide Y (NPY) receptors, galanin, galanin receptors, somatostatin, and somatostatin receptors, for the treatment of neurological and psychiatric diseases in humans and animals. The Company focuses on the development of an epilepsy treatment by means of an adeno-associated virus (AAV) vector carrying the transgenes for the neurotransmitter NPY and one of its receptors, the G protein-coupled receptor Y2.
Employees
5
Date Price Change Volume
04/26/04 SEK 2.210 -0.90% 5,917
03/26/03 SEK 2.230 -1.33% 8,844
02/26/02 SEK 2.260 -3.42% 45
01/26/01 SEK 2.340 +0.43% 5,479
31/26/31 SEK 2.330 +3.56% 959
  1. Stock Market
  2. Stocks
  3. LARK Stock